Syndax Achieves Commercial Status As Incyte-Partnered GVHD Drug Gets FDA Nod
US FDA approval of Niktimvo for third-line chronic GVHD, a competitor to Sanofi’s Rezurock, came less than two months ahead of anticipated approval of Syndax’s leukemia drug revumenib.
